Daily Medication Pearl: Betrixaban (Bevyxxa)

Article

Medication Pearl of the Day: Betrixaban (Bevyxxa)

Indication: Betrixaban (Bevyxxa) is a factor Xa (FXa) inhibitor indicated for the prophylaxis of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE.

Insight:

  • Dosing: The recommended dose of betrixaban is an initial single dose of 160 mg, followed by 80 mg once daily, taken at the same time each day with food.
  • Dosage forms: Capsules 40 mg and 80 mg.
  • Adverse events: Most common adverse reaction (incidence > 5%) is bleeding.
  • Mechanism of action: Betrixaban is an oral FXa inhibitor that selectively blocks the active site of FXa and does not require a cofactor (such as antithrombin III) for activity. Betrixaban inhibits free FXa and prothrombinase activity. By directly inhibiting FXa, betrixaban decreases thrombin generation. Betrixaban has no direct effect on platelet aggregation.
  • Manufacturer: Portola Pharmaceuticals

Sources:

BEVYXXA (fda.gov)

bevyxxa image - Google Search

Related Videos
Image credit:  Gorodenkoff | stock.adobe.com
Sun Screen, Photosensitivity, Pharmacy | Image Credit: sosiukin - stock.adobe.com
Catalyst Trial, Diabetes, Hypertension | Image Credit: grinny - stock.adobe.com
Image Credit: © Anastasiia - stock.adobe.com
Various healthy foods -- Image credit: New Africa | stock.adobe.com
LGBTQIA+ pride -- Image credit: lazyllama | stock.adobe.com
Image Credit: © Анастасія Стягайло - stock.adobe.com
Modern pharmacy building facade with large window showcasing the interior, as seen from the street view, promoting a welcoming atmosphere for customers. Frontal view. Generative AI - Image credit: Karrrtinki | stock.adobe.com
hematological cancer/Image Credit: © nikola-master - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.